IDEXX Laboratories: The Long View
What the filings say about its story, dilution and cash runway.
This page is information, not investment advice.
Sources used most:
- 10-K FY2025, filed Feb 20, 2026
- 10-Q Q2 2026, filed Aug 4, 2026
- Q3 2026 results release, Nov 2, 2026
- 2026 Investor Day presentation, Aug 13, 2026
- Q3 2026 prepared remarks, Nov 2, 2026
1. In one paragraph
Last updated Nov 12, 2026. Reflects the 10-K FY2025, the Q3 2026 release and the 10-Q for Q3 2026.
IDEXX sells diagnostics for pets. Vets buy its analyzers once, then keep buying the slides, reagents and test kits those analyzers use, and send samples to its network of about 80 reference labs. These recurring diagnostics made up about 79% of 2025 revenue of $4.30B, which grew 10.4% (our calculation)1. The rest comes from analyzers, practice software and imaging, water-quality tests and livestock tests. In 2025, 64% of revenue came from the US (10-K, note 3).
IDEXX revenue by product line, 2025 ($M)
Repeat purchases of lab tests and in-clinic supplies dominate; one-time sales of analyzers and systems are small.
Recurring pet diagnostics and softwareOne-time sales of analyzers and systemsWater, livestock and other tests
Show the data table
| Product line | Revenue ($M) |
|---|---|
| In-clinic analyzer supplies (VetLab consumables) | 1497 |
| Reference lab tests and consulting | 1424 |
| Rapid test kits (SNAP) | 349 |
| Software and imaging subscriptions and services | 276 |
| Water quality tests | 201 |
| In-clinic analyzers | 200 |
| Diagnostic services and accessories | 137 |
| Livestock, poultry and dairy tests | 132 |
| Software and imaging systems and hardware | 70 |
| Other (human medical tests and licensing) | 17 |
- Segments: Companion Animal Group (CAG, pet diagnostics, software and imaging) $3.95B, 92% of revenue; Water $201M; Livestock, Poultry and Dairy (LPD) $132M; Other $17M (10-K, note 3)1.
- No customer accounted for more than 10% of revenue in 2025 (10-K, note 2).
- IDEXX has never paid a dividend; it returns cash through buybacks (10-K, item 5).
2. Story so far
Last updated Nov 2, 2026. Reflects filings and releases through Nov 2, 2026, and Yahoo Finance price history.
In short: IDEXX grew revenue every year from 2021 to 2025, from $3.22B to $4.30B, and spent about as much on buybacks as it generated in free cash flow (operating cash flow minus capital spending; our calculation)2, while its share price swung widely. It launched its inVue Dx analyzer in late 2024, and in 2026 it changed chief executive, bought the AI software company CoVet and raised its 2026 forecasts at each quarterly report.
| Date | Milestone | Source |
|---|---|---|
| Q2 2021 | Buys the ezyVet cloud practice-management software and Vet Radar businesses for about $157M | 10-K FY2021 |
| Aug 5, 2021 → Oct 14, 2022 | ★ Reported by Yahoo Finance: the shares close at a then-record $705.76, then at $324.64 on Oct 14, 2022, 54% lower (our calculation) | Yahoo Finance |
| Feb 1, 2024 | Buys a US software and data platform business for about $77M, plus up to $30M of contingent payments | 10-K FY2023 |
| Late 2024 | ★ Launches IDEXX inVue Dx, an analyzer that automates cell examination (cytology) in the clinic using optics and AI | 10-K FY2025, item 1 |
| Apr 17, 2025 | Pays a judgment of about $80M, ending a lawsuit over royalties under an expired patent licence | Q3 2026 release |
| Aug 4, 2025 | Raises its 2025 outlook with Q2 results; reported by Yahoo Finance: the shares rise 27.5% that day | Q2 2025 release; Yahoo Finance |
| Nov 25, 2025 | Reported by Yahoo Finance: the shares close at a record $766.68 | Yahoo Finance |
| Jan 13, 2026 | ★ Names Michael Erickson, head of its point-of-care diagnostics business, to succeed Jay Mazelsky as chief executive from May 12, 2026; Mazelsky becomes executive chair until he retires in May 2027 | Release, Jan 13, 2026 |
| Feb 2, 2026 | First 2026 outlook: revenue of $4.63–4.72B, assuming US clinical visits fall again about as much as in 2025; reported by Yahoo Finance: the shares fall 4.6% | Q4 2025 release; 10-K; Yahoo Finance |
| Aug 13, 2026 | Investor day: management sets out multi-year goals of 10%+ organic revenue growth and 15%+ EPS growth, and previews its next analyzer, MultiCue Dx | Investor Day presentation |
| Sep 11, 2026 | Reported by Yahoo Finance: the shares close at $504.70, 34% below the record (our calculation) | Yahoo Finance |
| Sep 15, 2026 | Buys CoVet, maker of AI software that listens to consultations and writes clinical notes, for about $250M including an estimated $20M contingent payment (announced Sep 16) | Release, Sep 16, 2026; 10-Q Q3 2026, note 4 |
| Nov 2, 2026 | ★ IDEXX reports Q3 results and raises its 2026 revenue and EPS outlook a third time. Start of our coverage: Why IDEXX stock rose | Q3 release |
3. Latest quarter: did the story change?
Last updated Nov 12, 2026. Reflects Q3 2026 (release and call, Nov 2, 2026, and the 10-Q filed the same day) against Q2 2026.
Bottom line: According to its Nov 2 release, IDEXX raised its 2026 revenue and EPS forecasts for the third time this year, as recurring diagnostics revenue grew 11% and it placed more than 1,900 inVue Dx analyzers, even though its finance chief estimated that US clinical visits fell 1.8% in the quarter. Its forecast for operating margin (operating profit as a percentage of revenue) came down slightly, partly because of costs from buying CoVet.
How much IDEXX has raised its 2026 forecast since February (midpoints)
Both the revenue and the EPS midpoints have gone up at every update since February.
Midpoints and changes are our calculation from the company's ranges.
Show the data table
| Forecast date | Revenue midpoint ($M) | Revenue midpoint, change since Feb 2 ($M) | EPS midpoint ($) | EPS midpoint, change since Feb 2 ($) |
|---|---|---|---|---|
| Feb 2, 2026 | 4676 | 0 | 14.55 | 0 |
| May 5, 2026 | 4717.5 | 41.5 | 14.68 | 0.13 |
| Aug 4, 2026 | 4722.5 | 46.5 | 14.82 | 0.27 |
| Nov 2, 2026 | 4754 | 78 | 15.06 | 0.52 |
| Driver | Last quarter → this quarter | Management: before → now | Signal |
|---|---|---|---|
| Revenue | Q2 $1,217M (+10%; 9% organic) → Q3 $1,214M (+10%; 10% organic) | 2026 guide $4,700–4,745M (Aug 4) → $4,741–4,767M (Nov 2), including about $5M from CoVet | Better |
| Recurring pet diagnostics revenue (CAG Diagnostics recurring) | Q2 +11% (10% organic) → Q3 +11% (11% organic); US +10%, international +14% organic | 2026 organic growth 9.5–10.7% (Aug 4) → 10.3–11.0% (Nov 2) | Better |
| EPS (diluted) | Q2 $4.27 (+18%) → Q3 $4.01 (+18%; comparable +22%) | 2026 guide $14.69–14.94 (Aug 4) → $14.96–15.16 (Nov 2) | Better |
| Operating margin | Q2 35.0% → Q3 33.1% (up 1.0 point on a year earlier) | 2026 guide 32.3–32.5% (Aug 4) → 32.1–32.3% (Nov 2); the CFO put CoVet’s cost at about 0.3 point (prepared remarks) | Worse |
| US same-store clinical visits | Q2: not given in the release → Q3 about −1.8% (CFO estimate; 2025: about −2%) | 2026 outlook assumed a decline similar to 2025’s (Feb 20) → still falling | Watch |
Sources: Q2 2026 release, Q3 2026 release, Q3 prepared remarks, 10-K FY2025. Midpoints are our calculation3.
Unresolved questions: how much of CoVet’s up to $47.5M earn-out is paid, and whether 2027 guidance, due with Q4 results, again assumes fewer US vet visits.
4. Buybacks vs real dilution (5 years)
Last updated Nov 2, 2026. Reflects the 10-Ks for FY2021, FY2023 and FY2025, the 10-Q for Q2 2026 and the Q3 2026 release.
Dilution in one line: shares outstanding fell about 6.7% from Dec 31, 2020 to Dec 31, 2025, about 1.4% a year. If you owned 1% of IDEXX at the end of 2020, you’d own about 1.07% at the end of 2025 without buying more4. Buybacks were about four times the new shares issued. Our scale: Net reduction (the share count fell).
Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.
Change in the period Total since Dec 31, 2020
Shares outstanding at period end (all classes): 85.4M on Dec 31, 2020, 79.7M on Dec 31, 2025, −6.7% (our calculation). A bar below zero means the count fell (net buybacks).
Latest quarter-end (Jun 30, 2026): 78.9M shares, −1.1% since Dec 31, 2025.
| Period end | Shares outstanding | Change | Buybacks (fiscal year) | Stock-based pay (fiscal year) | Stock pay as % of revenue |
|---|---|---|---|---|---|
| FY2025 (Dec 31, 2025) | 79.7M | −2.3% | $1.2B | $60M | 1% |
| FY2024 (Dec 31, 2024) | 81.6M | −1.7% | $837M | $60M | 2% |
| FY2023 (Dec 31, 2023) | 83.0M | +0.2% | $72M | $60M | 2% |
| FY2022 (Dec 31, 2022) | 82.9M | −2.0% | $820M | $50M | 1% |
| FY2021 (Dec 31, 2021) | 84.6M | −1.0% | $747M | $38M | 1% |
| FY2020 (Dec 31, 2020) | 85.4M | — | $183M | $31M | 1% |
Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.
How we calculated this
New shares came from employee stock plans; IDEXX bought back more than it issued in every year except 2023.
| Bridge (millions of shares) | Shares |
|---|---|
| Start (Dec 31, 2020) | 85.45 |
| + Newly issued shares, employee stock plans (shares issued rose from 106.46M to 108.37M) | +1.91 |
| − Open-market buybacks (2021–2025) | −7.55 |
| − Shares surrendered by employees for taxes | −0.11 |
| + Treasury shares reissued (net) | +0.01 |
| End (Dec 31, 2025) | 79.71 |
Prices paid and received:
| Period | Shares bought back | Average price paid | Spent | Shares sold for cash | Average price received | Raised | Sources |
|---|---|---|---|---|---|---|---|
| 2021 | 1.28M | $588.58 | $756M | — | — | — | 10-K FY2021 |
| 2022 | 1.96M | $413.12 | $811M | — | — | — | 10-K FY2023 |
| 2023 | 0.16M | $468.84 | $73M | — | — | — | 10-K FY2023 |
| 2024 | 1.74M | $487.66 | $849M | — | — | — | 10-K FY2025, note 20 |
| 2025 | 2.41M | $506.07 | $1,220M | — | — | — | 10-K FY2025, note 20 |
| 2026 to date (Jan–Sep) | 1.37M | $588.14 | $805M | — | — | — | Q3 2026 release |
IDEXX made no public share offerings or at-the-market share sales in the period; employee-plan issuance is excluded here. It bought back 8.9M shares for about $4.5B from 2021 through September 2026; its most recent purchases cost more on average than in 2022–20256.
Basis and details
- Open-market repurchases on a trade-date basis, as reported; averages are the company’s. Costs include the 1% US excise tax from 2023. IDEXX has had no stock split in the period.
- Excluded from “sold for cash”: employee plan issuance; option exercises and the employee share purchase plan brought in $93M in 2025 (10-K, cash flow statement).
- Authorisation left: 2,353,970 shares at Sep 30, 2026, under a 78M-share programme with no expiry date, after IDEXX bought 198,600 shares for $111.8M in Q3 (10-Q Q3 2026, Part II, item 2).
- Management expected buybacks to cut average shares outstanding by about 2% in 2026 (Q3 release).
| Stock-based pay | 2021 | 2022 | 2023 | 2024 | 2025 | H1 2026 |
|---|---|---|---|---|---|---|
| $M | 38 | 50 | 60 | 60 | 60 | 32 |
| % of revenue (our calculation)7 | 1.2% | 1.5% | 1.6% | 1.5% | 1.4% | 1.4% |
Stock-based pay is small, at about 1.5% of revenue a year (10-K FY2025; 10-Q).
Insider transactions: Form 4 filings show net selling and no open-market buying in the 12 months to Nov 2, 2026; sales totalled about 57,600 shares, worth about $37.7M (our calculation)8.
- The largest sellers: former CEO and now executive chair Jay Mazelsky (23,326 shares, about $15.3M, after exercising options), executive vice president Nimrata Hunt, who agreed in March 2026 to leave her role (13,876; about $9.5M), and executive vice president George Fennell (11,345; about $7.3M).
- CEO Michael Erickson sold 5,371 shares (about $3.4M) in February 2026, before he took the job; directors Lawrence Kingsley and Sophie Vandebroek sold 2,203 and 1,464 shares.
- None of the filings with sales ticked the box for a prearranged Rule 10b5-1 trading plan.
Insider details
- Other entries are option exercises, shares withheld for taxes and director grants.
- The sales equal about 0.07% of the 78.8M shares outstanding on Jul 31, 2026 (our calculation).
- We read all 42 Form 4 filings made from Nov 3, 2025 to Sep 9, 2026, the latest as of Nov 2, 2026 (filings list); Hunt’s departure: 8-K, Mar 26, 2026.
5. Profit vs cash (latest FY and TTM)
Last updated Nov 2, 2026. Reflects the 10-K FY2025 and the Q3 2026 release. TTM = the four quarters to Sep 30, 2026 (our calculation)9.
IDEXX turns about all of its reported profit into free cash: free cash flow was 100% of net income in 2025 and 110% in the 12 months to September 2026. The 2025 figure was held down by an $80M legal payment that had been charged against profit in earlier years10.
| $M | FY2025 | TTM to Sep 30, 2026 (our calculation) |
|---|---|---|
| Revenue | 4,304 | 4,662 |
| Net income | 1,059 | 1,182 |
| Diluted EPS | $13.08 | Not calculated |
| Comparable EPS (company measure)11 | $12.55 | Not calculated |
| Operating cash flow | 1,182 | 1,419 |
| Capital spending | −125 | −115 |
| Free cash flow (company definition)10 | 1,057 | 1,304 |
Helps future profit or cash:
- Revenue already booked, cash still to come: IDEXX recognises revenue on analyzers placed under multi-year purchase commitments before it bills for them. These contract assets were $312.7M at Dec 31, 2025, up from $246.3M a year earlier, and $348.9M at Sep 30, 2026; they turn into bills as customers buy supplies ($60.9M of the opening balance was billed in the first nine months) (10-K, note 3; 10-Q Q3 2026, note 3).
Hurts future profit or cash:
- Incentives already given, cost still to come: IDEXX gives customers credits (“IDEXX Points”), or sometimes cash, when they sign multi-year purchase commitments. These are deducted from revenue over the contract: $250.1M was still to be deducted at Dec 31, 2025, and $62.0M was deducted in 2025; the balance was $276.9M at Sep 30, 2026, after $56.0M was deducted in the first nine months (10-K, note 3; 10-Q Q3 2026, note 3).
- Receivables used $69M of cash in 2025: sales recorded but not yet collected.
One-off / no lasting effect:
- Tax timing: $131M of non-cash deferred-tax expense was added back when reconciling 2025 profit to operating cash flow. It included the use of previously recorded tax benefits after US tax law changes let IDEXX deduct research and development costs sooner (10-K, item 7 and note 14).
- The ~$80M judgment paid on Apr 17, 2025 cut 2025 cash but not 2025 profit, which had absorbed the accrual in earlier years (10-K, item 7; Q3 release).
- Equity investments: 2026 operating expenses include a $5M loss on one; a non-operating gain on another added $0.03 to Q3 EPS (Q3 release).
The raw reconciling items (FY2025)
From the cash flow statement (10-K): depreciation and amortisation $145M; provision for uncollectible accounts $8M; deferred income taxes +$131M; stock-based pay $60M; other +$5M; working capital: receivables −$69M, inventories −$1M, accounts payable −$9M, deferred revenue +$7M, other assets and liabilities −$156M (including the ~$80M litigation payment and more cash used for customer commitment programmes). Income taxes paid in 2025: $167M (10-K, note 14).
Funding: how long without new money? Self-funding: $1,304M of free cash flow in the 12 months to Sep 30, 2026; $75M of notes due Feb 12, 2027, against $198M of cash at Sep 30, 2026 and $773M of undrawn credit availability at Sep 30, 202612.
Funding details
- As of Sep 30, 2026: cash $198M; debt about $849M: $474M drawn under its bank credit facility (including a $250M term loan) and $375M of senior notes (Q3 release, balance sheet)12.
- IDEXX borrows to fund buybacks as well as from cash flow: in 2025 it spent $1.22B on buybacks while free cash flow was $1.06B (10-K, item 7).
- The only financial covenant: debt no more than 3.5 times adjusted EBITDA (profit before interest, taxes, depreciation, amortisation and share-based pay); IDEXX was in compliance at Jun 30, 2026, with trailing adjusted EBITDA of $1.69B (10-Q).
- This is based on past cash flow; spending plans can change it.
Extends the runway:
- A $1.0B unsecured revolving credit line maturing Nov 12, 2030; $773M was available at Sep 30, 2026; the leverage ratio was 0.5 to 1, against a 3.5 to 1 ceiling (8-K, Nov 13, 2025; 10-Q Q3 2026).
Shortens the runway:
- Senior notes: $75M at 3.72% due Feb 12, 2027 (a further $75M was repaid on Sep 4, 2026); $100M at 4.19% due Mar 14, 2029; $200M at 2.50% due April 2030 (10-Q, note 11; Q3 release).
- The $250M term loan matures Nov 12, 2028 (10-K, item 7).
- Buybacks are discretionary; $805M in the first nine months of 2026.
Conditional:
- The credit agreement lets IDEXX add up to $250M of extra credit lines or term loans; these are not committed by the banks (8-K, Nov 13, 2025).
6. Customer and contract exposure
Last updated Nov 12, 2026. Reflects the 10-K FY2025 and the 10-Q for Q3 2026.
No customer accounts for more than 10% of revenue. The bigger dependencies are on vets’ visit numbers, on large corporate hospital groups that negotiate hard and in some cases run rival labs, on one supplier for its chemistry slides, and on currencies: 36% of revenue comes from outside the US.
IDEXX revenue by region, 2025 ($M)
The US provides about two-thirds of revenue; Europe, the Middle East and Africa about a fifth.
Show the data table
| Region | Revenue ($M) |
|---|---|
| United States | 2753 |
| Europe, Middle East and Africa | 937 |
| Asia Pacific | 356 |
| Canada | 167 |
| Latin America and Caribbean | 90 |
Customer and contract details
- Customers: no customer accounted for more than 10% of consolidated revenue in 2025 (10-K, note 2).
- Multi-year commitments: IDEXX estimated about $5.0B of future revenue from customers’ multi-year purchase commitments at Dec 31, 2025, and about $5.3B at Sep 30, 2026: about 7% in the rest of 2026, 28% in 2027, 25% in 2028, 18% in 2029 and 22% later (10-K, note 3; 10-Q Q3 2026, note 3).
- Corporate groups: a growing share of US vet hospitals belongs to corporations such as Mars (owner of Banfield, BluePearl and VCA) and National Veterinary Associates, and many independents buy through consortiums that seek lower prices. Mars also owns the competing Antech Diagnostics and Heska; IDEXX warns that hospitals these companies buy may move their testing to their own labs (10-K, risk factors).
- Supplier: Ortho-Clinical Diagnostics, part of QuidelOrtho, supplies certain Catalyst chemistry slides under agreements currently scheduled to expire in December 2044, subject to early termination in specified circumstances (after a notice of non-extension they run through Dec 31 of the twelfth year after notice, no later than 2044); IDEXX must buy its requirements for its current slide menu from Ortho as long as Ortho can supply them (10-K, item 1).
- Currency: 36% of 2025 revenue came from customers outside the US, and about 23% came from products made or bought in dollars and sold in local currencies (10-K, risk factors and item 7).
- Distributors: outside the US, IDEXX sells partly through distributors, which can also sell rivals’ products (10-K, risk factors).
7. IDEXX’s strategy for long-term growth
Last updated Nov 2, 2026. Reflects the 10-K FY2025, the Q3 2026 release and call, and the Aug 13, 2026 investor day.
IDEXX’s core market is under pressure from fewer US vet visits, consolidation among its customers and well-funded rivals. Management’s answer is to sell more tests per visit: more of its analyzers in clinics, new tests and platforms on them, software that ties practices to IDEXX, and annual price increases. Against its multi-year goal of 10%+ organic growth, it grew 10% a year in 2020–2025 by its own measure and expects 9.3–10.0% in 2026.
Pressure on the core business
Visits are falling, and IDEXX has relied on more testing per visit and on price.
- Visits: US same-store clinical visits fell about 2% in 2025, while US diagnostics revenue per practice grew about 6% (10-K, item 7). The CFO estimated a 1.8% fall in visits in Q3 2026 (Q3 prepared remarks).
- Price: the CFO said Q3 recurring diagnostics growth included about 4% from higher net prices worldwide (Q3 prepared remarks).
- Customers: corporate hospital groups and buying consortiums use their scale to seek lower prices, and some run their own labs (10-K, risk factors).
- Competitors: in North America IDEXX names Mars’s Antech Diagnostics and Heska, and Zoetis (including Abaxis); in software, Covetrus is its largest competitor in North America and the UK. It also warns that new competitors may use AI (10-K, item 1 and risk factors).
- Patents: IDEXX says no single patent is material and does not expect expiring patents to have a material effect (10-K, item 1 and item 7).
The strategy in management’s words
IDEXX calls its approach “Technology for Life” (CEO, Q2 2026 release). The 10-K says the strategy is to increase testing in vet practices “by placing IDEXX VetLab instruments and increasing instrument utilization of consumables” (10-K, item 7).
- Analyzers in clinics: the premium installed base (Catalyst chemistry, premium hematology, SediVue urine and inVue Dx analyzers) reached about 164,000 at the end of 2025 (our calculation)13; at its investor day IDEXX described a “long runway” to expand it more than threefold (Investor Day presentation).
- New platforms: inVue Dx (launched late 2024) examines cells, including fine-needle aspirates of lumps; MultiCue Dx, its next in-clinic analyzer, is in development and will be presented at an investor session on Jan 18, 2027 (Q3 release; Investor Day presentation).
- New tests: Cancer Dx, a cancer screening panel run by its reference labs, became a multi-cancer panel in 2026; IDEXX says it costs as little as $15 in the US when added to most routine panels (Investor Day presentation). New Catalyst tests include proBNP, a heart test launched in North America in 2026 (Q3 prepared remarks; Investor Day presentation).
- Software: IDEXX bought ezyVet and Vet Radar for about $157M (2021), a software and data business for about $77M (2024) and CoVet (September 2026). CoVet’s total acquisition consideration was about $250M, including an estimated $20M contingent payment and about $4M of holdbacks; cash paid net of acquired cash was $223.4M14. The earn-out (an additional payment tied to agreed targets) could reach $47.5M, depending on CoVet’s revenue in 2027–29, and about $230M of the price is goodwill (the price above the fair value of the identifiable net assets) (10-Q Q3 2026, notes 4 and 18). CFO Andrew Emerson said CoVet’s annualised revenue run rate was about $20M and that acquisition-related impacts would reduce 2026 EPS by about $0.13 (10-K FY2021; 10-K FY2023; Q3 prepared remarks).
Multi-year goals (investor day, Aug 13, 2026)
- Organic revenue growth of 10% or more a year; comparable operating margin up 0.5–1.0 point a year; comparable EPS growth of 15% or more a year, assuming stable currencies (Investor Day presentation).
- IDEXX said new innovations add 2 percentage points or more to long-term growth of its recurring pet diagnostics revenue (Investor Day presentation).
- inVue Dx: a goal of 5,500 placements in 2026, with recurring revenue of $3,500–5,500 a year per analyzer (Q3 prepared remarks); the CEO also referred to a five-year goal of 20,000 placements, according to Investing.com’s call transcript, which we have not checked against the company’s recording (transcript).
Is it working?
So far, growth has come from more analyzers in clinics and more testing, not from more visits; the 2026 forecast is a little below the 10%+ goal.
IDEXX revenue and premium analyzers installed in clinics, 2020–2025
Revenue rose about 59% and the installed base of premium analyzers about 73% over five years.
Installed base: Catalyst, premium hematology and SediVue Dx analyzers, plus inVue Dx from 2025; growth rates are our calculation.
Show the data table
| Year | Revenue ($M) | Premium analyzers installed (thousands) |
|---|---|---|
| 2020 | 2707 | 94.9 |
| 2021 | 3215 | 108.0 |
| 2022 | 3367 | 121.8 |
| 2023 | 3661 | 135.0 |
| 2024 | 3898 | 147 |
| 2025 | 4304 | 164 |
- Growth: by IDEXX’s measure, organic revenue grew 10% a year in 2020–2025, operating margin rose about 1 point a year and comparable EPS grew 16% a year; the 2026 guide is organic growth of 9.3–10.0% and EPS of $14.96–15.16 (Investor Day presentation; Q3 release).
- inVue Dx: about 6,000 installed at the end of 2025 and nearly 11,000 by Sep 30, 2026; the CEO said IDEXX is “well on track to exceed” the 2026 goal (10-K; Q3 release; Q3 prepared remarks).
- Cancer Dx: more than 14,000 customers had ordered and run it, the CEO said on the Nov 2 call, according to Investing.com’s transcript (transcript); its revenue is not disclosed.
- Software: veterinary software, services and imaging revenue grew 11% in Q3 2026 to $97M (Q3 release). CoVet’s revenue in 2026 is expected to be about $5M (Q3 release).
- Margins: 2026 operating margin is guided at 32.1–32.3%, up 0.5–0.7 point, inside the 0.5–1.0 point goal (Q3 release).
Strategy: what to watch
- MultiCue Dx: what it tests and when it launches (investor session Jan 18, 2027).
- US clinical visits: the assumption in the 2027 outlook, and whether testing per visit keeps rising.
- inVue Dx placements and recurring revenue per analyzer, and Cancer Dx revenue if IDEXX discloses it.
- CoVet: its effect on margins in 2027, and the earn-out of up to $47.5M tied to its revenue in 2027–29.
8. What to watch
Last updated Nov 12, 2026.
| Date | Item | Source |
|---|---|---|
| Jan 18, 2027 | Investor and analyst session at the VMX conference, featuring the MultiCue Dx analyzer | Q3 release |
| Feb 12, 2027 | $75M of 3.72% senior notes mature | 10-Q Q2 2026 |
| Not announced as of Nov 12, 2026 | Q4 and full-year 2026 results | IR calendar |
| May 2027 | Jay Mazelsky retires as executive chair after the annual meeting | Release, Jan 13, 2026 |
| Nov 12, 2028 | $250M term loan matures | 10-K FY2025 |
Valuation at each update
| Update | Close | Market value | EV | P/S | EV/sales | P/E | P/FCF | Revenue growth | FCF margin | Net cash (debt) | Basis |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | $671.64 (Nov 2) | $52.9B | $53.7B | 11.6× | 11.8× | 46.4× | 42.2× | +13% | 28% | ($772M) | 12 months to Jun 30, 2026 |
| Nov 12, 2026 | $698.02 (Nov 12) | $55.0B | $55.6B | 11.8× | 11.9× | 46.5× | 42.2× | +12% | 28% | ($651M) | 12 months to Sep 30, 2026 |
Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 2, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Nov 2, 2026 price: Nasdaq historical close. Nov 12, 2026 price: official close, Yahoo Finance, CNBC.
Notes and calculations
-
2025 revenue $4,303.7M; 2024 $3,897.5M; growth = 4,303.7 ÷ 3,897.5 − 1 = 10.4%. Recurring CAG diagnostics $3,407.2M ÷ $4,303.7M = 79.2% (the 10-K says “approximately 79%”). CAG $3,953.3M ÷ $4,303.7M = 91.9%. US $2,752.8M ÷ $4,303.7M = 64.0% (10-K, note 3). ↩ ↩2
-
2021–2025 open-market buybacks: $755.5M + $810.9M + $72.6M + $848.9M + $1,220.3M = $3,708M. Free cash flow = operating cash flow − capital spending: ($755.5M + $543.0M + $906.5M + $929.0M + $1,181.8M) − ($119.5M + $148.8M + $133.6M + $120.9M + $124.7M) = $4,315.8M − $647.5M = $3,668M (company XBRL data from the 10-Ks). ↩
-
Midpoints of the 2026 ranges. Revenue: ($4,632M + $4,720M) ÷ 2 = $4,676M (Feb 2); ($4,675M + $4,760M) ÷ 2 = $4,717.5M (May 5); ($4,700M + $4,745M) ÷ 2 = $4,722.5M (Aug 4); ($4,741M + $4,767M) ÷ 2 = $4,754M (Nov 2). EPS: ($14.29 + $14.80) ÷ 2 = $14.545; ($14.45 + $14.90) ÷ 2 = $14.675; ($14.69 + $14.94) ÷ 2 = $14.815; ($14.96 + $15.16) ÷ 2 = $15.06. Changes since Feb 2: revenue +$41.5M, +$46.5M, +$78M; EPS +$0.13, +$0.27, +$0.515 (shown as $0.52); the table rounds EPS midpoints to cents (Q4 2025 release; Q1 2026 release; Q2 2026 release; Q3 2026 release). ↩
-
Balance-sheet counts: 85.449M at Dec 31, 2020 and 79.712M at Dec 31, 2025. Change = 79.712 ÷ 85.449 − 1 = −6.7%; annual rate = (79.712 ÷ 85.449)^(1 ÷ 5) − 1 = −1.4%; ownership = 1% × 85.449 ÷ 79.712 = 1.07%. Bridge: shares issued 108.369M − 106.457M = 1.912M; open-market buybacks 1.283M + 1.963M + 0.155M + 1.741M + 2.411M = 7.553M; employee surrenders 0.029M + 0.021M + 0.020M + 0.019M + 0.016M = 0.105M; treasury shares rose 28.657M − 21.008M = 7.649M, so about 0.009M were reissued (company XBRL data from the 10-Ks). Cover pages: 85,426,080 (Feb 9, 2021); 79,624,034 (Feb 13, 2026); 78,781,116 (Jul 31, 2026). ↩ ↩2
-
7.553M ÷ 1.912M = 4.0. ↩
-
Shares: 7.553M (2021–2025) + 1.369M (Jan–Sep 2026) = 8.92M. Cost: $755.5M + $810.9M + $72.6M + $848.9M + $1,220.3M + $804.7M = $4,513M. ↩
-
Stock-based pay ÷ revenue: $37.8M ÷ $3,215.4M; $49.8M ÷ $3,367.3M; $59.7M ÷ $3,661.0M; $60.3M ÷ $3,897.5M; $60.0M ÷ $4,303.7M; $32.4M ÷ $2,357.4M (H1 2026; 10-Q). ↩
-
Sum of code S transactions on 42 Form 4 filings filed Nov 3, 2025 to Sep 9, 2026: 57,585 shares; value = Σ shares × reported price = $37.7M. Per seller: Mazelsky 23,326 ($15.3M); Hunt 13,876 ($9.5M); Fennell 11,345 ($7.3M); Erickson 5,371 ($3.4M); Kingsley 2,203 ($1.2M); Vandebroek 1,464 ($0.9M). 57,585 ÷ 78,781,116 = 0.07%. Ledger: documents/gc-project-wmsm/fact-checks/idxx-form4-ledger-2026-11-02.md. ↩
-
FY2025 − first nine months of 2025 + first nine months of 2026. Revenue: $4,303.7M − $3,213.1M + $3,571.6M = $4,662.2M. Net income: $1,059.5M − $811.3M + $934.0M = $1,182.2M. Operating cash flow: $1,181.8M − $826.0M + $1,063.1M = $1,418.9M. Capital spending: $124.676M − $95.242M + $85.560M = $114.994M, rounded to $115.0M (10-K; Q3 release, which gives about $1,419M, $115M and $1,182M). ↩
-
Free cash flow = operating cash flow − purchases of property and equipment: $1,181.8M − $124.7M = $1,057.1M (FY2025); $1,418.9M − $115.0M = $1,303.9M (TTM). Ratio to net income: $1,057.1M ÷ $1,059.5M = 99.8%; $1,303.9M ÷ $1,182.2M = 110%. ↩ ↩2
-
Company reconciliation for 2025: diluted EPS $13.08 − $0.35 tax benefit from share-based compensation − $0.08 from the reduced litigation accrual − $0.10 from currency changes = comparable EPS $12.55 (Q4 2025 release). IDEXX does not publish a trailing-12-month comparable EPS. ↩
-
At Sep 30, 2026: cash $197.5M; line of credit $474.0M + current portion of long-term debt $75.0M + long-term debt $299.9M = $848.9M. Senior notes $75M + $100M + $125M + $75M = $375M. Undrawn revolver at Sep 30, 2026: $773.2M, after $2.8M of letters of credit (10-Q Q3 2026, note 11). ↩ ↩2
-
Year-end installed base, in thousands (Catalyst + premium hematology + SediVue Dx, + inVue Dx in 2025): 2020: 49.6 + 34.6 + 10.7 = 94.9 (10-K FY2021); 2021: 56.6 + 38.2 + 13.2 = 108.0; 2022: 63.1 + 43.1 + 15.6 = 121.8; 2023: 69.1 + 47.8 + 18.1 = 135.0 (10-K FY2023); 2024: 74 + 52 + 21 = 147; 2025: 78 + 56 + 24 + 6 = 164 (10-K FY2025, item 7). Growth 2020–2025: 164 ÷ 94.9 − 1 = 73%; revenue $4,303.7M ÷ $2,706.7M − 1 = 59%. ↩
-
10-Q Q3 2026, note 4 (consideration about $250M, including estimated contingent consideration of $20M and holdbacks of about $4M) and cash flow statement (acquisition of a business, net of cash acquired, $223.4M). The CFO had said IDEXX deployed about $335M on CoVet and buybacks in Q3 (prepared remarks). ↩
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.
About IDEXX Laboratories: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)